文献速递眼底病与葡萄膜炎

稳定期激光治疗的增殖性糖尿病视网膜病变眼黄斑毛细血管无灌注

Macular Capillary Nonperfusion in Eyes With Stable Laser-Treated Proliferative Diabetic Retinopathy.
PubMed 文献 · JAMA Ophthalmol · 2025-01-01

这项在英国单中心开展的前瞻性观察性队列研究纳入63例参与者共88眼,均为激光治疗后稳定的增殖性糖尿病视网膜病变伴黄斑毛细血管无灌注。12个月内黄斑中心凹无血管区面积平均增加2.26%(95%CI 0.29%-4.26%;P=0.03),7例参与者(9.3%)视力下降至少5个字母,基线浅层血管密度较低与视力下降相关。

要点

  • 12个月内黄斑中心凹无血管区面积平均增加2.26%(95%CI 0.29%-4.26%;P=0.03)。
  • 7例参与者(9.3%)在12个月时视力下降至少5个字母。
  • 视力下降≥5字母者基线3×3mm扫描浅层血管密度较低(36.7 vs 33.5;P=0.006)。

核心结论

  • 在激光治疗后周边视网膜稳定且伴黄斑毛细血管无灌注的眼中,黄斑中心凹无血管区面积在12个月内恶化。
  • 视力下降不常见,且在基线浅层血管密度降低的眼中更常见,而非中心凹无血管区参数。
  • 可能需要更长时间的试验来观察更多≥5个字母变化的事件。

研究设计与样本

  • 前瞻性观察性队列研究,在英国单中心开展。
  • 纳入至少1眼为激光治疗后稳定的增殖性糖尿病视网膜病变伴黄斑毛细血管无灌注,且最佳矫正视力字母评分至少54(Snellen等效≥20/80)的参与者。
  • 招募时间为2019年12月至2021年8月,随访12个月;数据分析时间为2024年5月至7月。
  • 队列包括63例参与者和88眼;平均(SD)年龄57.4(11.9)岁;男性41例(65.1%),女性22例(34.9%)。
  • 采用线性混合效应模型(非结构化方差)分析12个月内最佳矫正视力、低亮度视力及OCTA指标变化,并考虑同一参与者合格研究眼与重复测量之间的相关性。

主要发现

  • 基线平均最佳矫正视力和低亮度视力ETDRS字母评分分别为77.52(SD 8.0;约Snellen等效20/32)和68.33(SD 8.9;Snellen 20/40);12个月时分别为78.76(SD 8.3;Snellen 20/25)和70.20(SD 8.1;Snellen 20/40)。
  • 7例参与者(9.3%)在12个月时视力下降至少5个字母。
  • 线性混合效应分析显示中心凹无血管区面积在12个月内恶化,6个月时较基线平均增加1.80%(95%CI 0.01%-3.63%;P=0.05),12个月时较基线平均增加2.26%(95%CI 0.29%-4.26%;P=0.03)。
  • 视力下降≥5个字母的眼中,基线3×3mm扫描浅层血管密度较低(均值[SD] 36.7[4.8] vs 33.5[2.0];P=0.006),黄斑旁区浅层血管密度也较低(38.7[5.6] vs 34.7[2.6];P=0.005)。
  • 12个月时视力下降≥5个字母与任何基线中心凹无血管区参数之间未发现关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文在结论中提出可能需要更长时间的试验来观察更多≥5个字母变化的事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Some eyes with proliferative diabetic retinopathy (PDR) treated to stability with panretinal photocoagulation (PRP) continue to lose vision without diabetic macular edema. One presumed cause is macular capillary nonperfusion (CNP)-associated ischemia or infarction. Natural history data of macular CNP might guide treatment trials for it. OBJECTIVE: To assess visual function and optical coherence tomography angiography (OCTA) changes over 12 months in PRP-treated stable eyes with PDR and macular CNP. DESIGN, SETTING, AND PARTICIPANTS: This prospective observational cohort study was conducted in a single center in the United Kingdom. Participants had stable laser-treated PDR in at least 1 eye with macular CNP and a best-corrected visual acuity (BCVA) letter score of at least 54 (Snellen equivalent ≥20/80) using Early Treatment Diabetic Retinopathy Study (ETDRS) chart. Recruitment was from December 2019 to August 2021 and follow-up for 12 months; data were analyzed from May to July 2024. MAIN OUTCOMES AND MEASURES: Changes in BCVA, low-luminance visual acuity (LLVA), and OCTA metrics over 12 months using linear mixed-effects models with unstructured variance accounting for within-participant correlation between the eligible study eye and repeated measures across time. RESULTS: The cohort included 63 participants and 88 eyes. The mean (SD) age was 57.4 (11.9) years; 41 were male (65.1%) and 22 female (34.9%). Mean BCVA and LLVA ETDRS letter scores were 77.52 (SD, 8.0; approximate Snellen equivalent, 20/32) and 68.33 (SD, 8.9; Snellen, 20/40) at baseline and 78.76 (SD, 8.3; Snellen 20/25) and 70.20 (SD, 8.1; Snellen, 20/40) at 12 months. However, 7 participants (9.3%) lost at least 5 letters of visual acuity at 12 months. Linear mixed-effects analysis showed the foveal avascular zone (FAZ) area deteriorated over 12 months, with a mean increase of 1.80% (95% CI, 0.01%-3.63%; P = .05) at 6 months and 2.26% (95% CI, 0.29%-4.26%; P = .03) from baseline. Eyes that lost 5 or more letters had lower baseline superficial vascular density in both the 3 × 3-mm scan (mean [SD], 36.7 [4.8] vs 33.5 [2.0]; P = .006) and parafoveal area (38.7 [5.6] vs 34.7 [2.6]; P = .005). No association was found between a loss of 5 or more letters at 12 months and any baseline FAZ parameters. CONCLUSIONS AND RELEVANCE: This study found that FAZ area deteriorated over 12 months in eyes with stable laser-treated peripheral retina in eyes and macular CNP. Vision loss was uncommon and more prevalent in eyes with decreased SVD at baseline rather than FAZ parameters. Longer trials may be required to observe more events of change of 5 or more letters.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Thottarath S, Tsai WS, Gurudas S, et al. Macular Capillary Nonperfusion in Eyes With Stable Laser-Treated Proliferative Diabetic Retinopathy. JAMA Ophthalmol. 2025. PMID: 39602145. doi:10.1001/jamaophthalmol.2024.5105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。